Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy.

@article{Gerrard2013OutcomeAP,
  title={Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy.},
  author={Mary Gerrard and Ian M Waxman and Richard Sposto and Anne Auperin and Sherrie L. Perkins and Stanton Goldman and Lauren Harrison and Ross Pinkerton and Keith McCarthy and Martine Raphael and Catherine Patte and Mitchell S Cairo},
  journal={Blood},
  year={2013},
  volume={121 2},
  pages={278-85}
}
Mediastinal large B-cell lymphoma (MLBL) represents 2% of mature B-cell non-Hodgkin lymphoma in patients ≤ 18 years of age. We analyzed data from childhood and adolescent patients with stage III MLBL (n = 42) and non-MLBL DLBCL (n = 69) treated with Group B therapy in the French-American-British/Lymphome Malins de Burkitt (FAB/LMB) 96 study. MLBL patients had a male/female 26/16; median age, 15.7 years (range, 12.5-19.7); and LDH < 2 versus ≥ 2 × the upper limit of normal, 23:19. Six MLBL… CONTINUE READING